Targanta Company Description
Targanta Therapeutics' mission is to build a better antibiotic. The biopharmaceutical company is developing new treatments for severe, drug-resistant bacterial infections, including those that attack the skin, blood, and bone. Its lead candidate is oritavancin, which may treat both skin and blood infections; the drug was first discovered by Eli Lilly and further developed by InterMune, from whom Targanta acquired the rights in 2005. The company plans to develop other antibiotics in addition to oritavancin; it is working on one early-stage candidate that may fight osteomyelitis, an inflammation of the bone caused by infection.
View the Comprehensive Company Description for Targanta
The Company Description provides a historical perspective of Targanta's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Targanta's evolution in the marketplace.
